Humacyte, Inc. (HUMAW)
| Market Cap | 181.09M -17.2% |
| Revenue (ttm) | 2.02M +289.9% |
| Net Income | -95.22M |
| EPS | -0.55 |
| Shares Out | 222.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 514,447 |
| Open | 0.0080 |
| Previous Close | 0.0090 |
| Day's Range | 0.0080 - 0.0100 |
| 52-Week Range | 0.0020 - 0.5185 |
| Beta | 2.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About HUMAW
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would tar... [Read more]
News
Humacyte announces FDA acceptance of CTEV IND application
Humacyte (HUMA) announced that the FDA has accepted its investigational new drug, or IND, application for a first-in-human clinical study of the coronary tissue engineered vessel in coronary artery by...
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at mul...
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North ...
Humacyte price target lowered to $1.25 from $1.50 at TD Cowen
TD Cowen lowered the firm’s price target on Humacyte (HUMA) to $1.25 from $1.50 and keeps a Buy rating on the shares. The firm said they are encouraged by the…
Humacyte Slides: Corporate presentation
Humacyte has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
Humacyte Transcript: Study result
The V012 phase III interim analysis showed ATEV significantly increased catheter-free days and reduced infections versus AVF in women on hemodialysis, with a favorable safety profile and superior maturation rates. These results support a planned FDA filing for use in high-risk patients.
Humacyte Press release: Study result
Humacyte issued a press release on June 15, 2026, disclosing material business information to investors.
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of t...
Humacyte price target raised to $4 from $3 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Humacyte (HUMA) to $4 from $3 and keeps a Buy rating on the shares. The company reported positive top-line results from the…
Humacyte 47.62M share Spot Secondary priced at $1.05
The deal priced at low end of $1.05-$1.15 range. Barclays, BTIG and Titan Partners are acting as joint book running managers for the offering.
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte TBA Spot Secondary; price range $1.05-$1.15
Barclays, BTIG and Titan Partners are acting as joint book running managers for the offering.
Humacyte announces V012 study of ATEV meets primary endpoint
Humacyte (HUMA) announced top-line interim results for the V012 Phase 3 study of the acellular tissue engineered vessel, or ATEV, in female patients for dialysis access. In a prespecified interim…
Humacyte announces common stock offering, no amount given
Humacyte (HUMA) announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Humacyte. Humacyte intends to…
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 -
Humacyte Transcript: AGM 2026
The meeting covered director elections, executive compensation, auditor ratification, and an increase in authorized shares, with all proposals passing by strong margins. No questions were raised by stockholders during the session.
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humacyte price target raised to $2 from $1 at Benchmark
Benchmark raised the firm’s price target on Humacyte (HUMA) to $2 from $1 and keeps a Speculative Buy rating on the shares. The firm updated estimates for Symvess and Humacyte’s…
Humacyte announces presentation at VASA meeting on self-repair ATEV
Humacyte (HUMA) announced the presentation of research providing evidence of self-repair of the acellular tissue engineered vessel, ATEV, after cannulation for dialysis access at the Vascular Access S...
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle ...
Humacyte reports Symvess under contract with Strategic Acquisition Center of VA
Humacyte (HUMA) announced that Symvess is now under contract with the with Strategic Acquisition Center of the U.S. Department of Veterans Affairs. The SAC contract makes Symvess more easily accessibl...
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee and s...
Humacyte price target raised to $1.50 from $1 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on Humacyte (HUMA) to $1.50 from $1 and keeps a Buy rating on the shares. The firm updated its model…
Humacyte reports Q1 EPS (9c), consensus (12c)
Reports Q1 revenue $495,000, consensus $1.46M. “We have seen expansion in the commercial uptake of Symvess. We also recognize that more rapid growth and expansion of sales is necessary and…